Investors Sell Shares of Pfizer, Inc. (PFE) on Strength (PFE)
Investors sold shares of Pfizer, Inc. (NYSE:PFE) on strength during trading hours on Monday. $74.60 million flowed into the stock on the tick-up and $203.75 million flowed out of the stock on the tick-down, for a money net flow of $129.15 million out of the stock. Of all equities tracked, Pfizer had the highest net out-flow for the day. Pfizer traded up $0.12 for the day and closed at $35.30
Several research firms have recently weighed in on PFE. BMO Capital Markets restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Friday. J P Morgan Chase & Co set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Finally, UBS AG set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.48.
The company has a market capitalization of $209,697.67, a P/E ratio of 14.07, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS. analysts forecast that Pfizer, Inc. will post 2.59 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.64%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.
In other news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the sale, the insider now directly owns 74,506 shares in the company, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock worth $12,796,098 in the last ninety days. Insiders own 0.06% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Shine Investment Advisory Services Inc. purchased a new position in Pfizer during the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Herndon Capital Management LLC purchased a new position in Pfizer during the 2nd quarter valued at about $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new position in Pfizer during the 1st quarter valued at about $121,000. 69.36% of the stock is owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.